Sylvant® is currently licensed in EU, US and other countries worldwide including Canada, Korea and Mexico and is an interleukin-6 (IL-6) antagonist indicated for the treatment of patients with idiopathic multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. By binding to the IL-6 ligand, Sylvant® therefore blocks the signaling cascade that would lead to proliferation of immune cells.
Caphosol® is indicated for the treatment and prevention of oral mucositis, a complication of cancer treatment (including radiation and chemotherapy). It contains a high concentration of phosphate and calcium ions to lubricate the mucosa of the mouth, tongue and oropharynx and help maintain the integrity of the oral cavity. Caphosol® is available as ampules or in dispersible form.
Qarziba® is currently licensed in the EU for the treatment of high risk neuroblastoma, a rare form of cancer arising from neural crest cells, in patients aged 12 months and above. The molecule is a monoclonal chimeric antibody that binds to the GD2 antigen on neuroblastoma cells, and activates an immune response that targets these cancer cells.
Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK
Fotivda® is a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI): an oral, once-daily inhibitor of all three vascular endothelial growth factor (VEGF) receptors. Fotivda® is indicated in the EU for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naīve following disease progression after one prior treatment with cytokine therapy for advanced RCC.
Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, UK, Norway, Iceland, Lichtenstein